Trial
NCT04931862
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Wave Life Sciences USA, Inc.
Collaborators
—
Condition
ALS
Intervention
WVE-004
Why stopped
Despite robust, sustained reductions in poly(GP), no clinical benefit was seen at 24 weeks, and reductions in poly(GP) were not associated with stabilization in functional outcomes. Based on these data, Wave decided to stop development of WVE-004.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-23